PeptideJournal
Reference14 min read

Peptide Modifications: PEGylation, Lipidation, Cyclization

A native peptide injected into the bloodstream faces a hostile environment. Proteases cleave it within minutes. The kidneys filter anything under ~60 kDa into the urine. The gastrointestinal tract destroys what is swallowed.

A native peptide injected into the bloodstream faces a hostile environment. Proteases cleave it within minutes. The kidneys filter anything under ~60 kDa into the urine. The gastrointestinal tract destroys what is swallowed. Without modification, even the most potent peptide has a plasma half-life measured in single-digit minutes --- too short to be a practical drug.

This is why semaglutide lasts a week instead of two minutes. Why tirzepatide can be dosed weekly. Why oral peptide drugs are finally becoming possible. The answer, in every case, is chemical modification of the peptide itself.

Three families of modification dominate modern peptide drug design: PEGylation (attaching polyethylene glycol chains), lipidation (attaching fatty acid chains), and cyclization (constraining the peptide's shape). Each solves the stability problem through a different physical mechanism, and each carries trade-offs that determine when it is the right choice.

Table of Contents

Why Peptides Need Modification

Unmodified peptides have three fundamental vulnerabilities as drugs:

Proteolytic degradation. Enzymes in the blood, tissues, and gut cleave peptide bonds. Dipeptidyl peptidase-4 (DPP-4), for example, clips the two N-terminal amino acids from native GLP-1 within about 2 minutes, rendering it inactive. Other peptidases attack from the C-terminus or at internal sites.

Renal clearance. The kidneys filter molecules smaller than approximately 60 kDa. Most therapeutic peptides weigh between 1 and 10 kDa --- small enough to be cleared rapidly into the urine. A peptide that survives protease attack is still eliminated by filtration.

Low oral bioavailability. The GI tract is designed to break down proteins into amino acids. Stomach acid denatures peptide structure. Pancreatic proteases (trypsin, chymotrypsin, elastase) cleave peptide bonds. The intestinal epithelium blocks passage of large hydrophilic molecules. Together, these barriers typically reduce oral peptide bioavailability to below 2%.

Every peptide modification strategy addresses one or more of these problems. The goal is always the same: make the peptide last long enough and reach its target in sufficient quantity to produce a therapeutic effect.

PEGylation: The Size Shield

PEGylation is the covalent attachment of polyethylene glycol (PEG) chains to a peptide or protein. PEG is a water-soluble, chemically inert polymer composed of repeating ethylene oxide units: -(CH2-CH2-O)n-. PEGylation was one of the earliest modification strategies and remains widely used.

How It Works

When a PEG chain (typically 5 to 40 kDa) is attached to a peptide, the resulting conjugate has a much larger hydrodynamic radius --- the effective size of the molecule as it moves through solution. A 10 kDa peptide conjugated to a 40 kDa PEG behaves hydrodynamically as if it were a 300-500 kDa globular protein. This size increase has two direct consequences:

Reduced renal clearance. The PEGylated peptide is too large to pass through the kidney's glomerular filtration barrier, dramatically slowing elimination and extending the half-life from hours to days.

Steric protection. The PEG chain creates a hydrated "cloud" around the peptide, physically shielding it from proteases and immune recognition. Enzymes that would normally cleave exposed peptide bonds cannot easily access their target through the PEG layer.

The Chemistry

PEGylation uses reactive PEG derivatives that target specific functional groups on the peptide. Common approaches include:

  • Amine-reactive PEGylation: PEG-NHS esters react with lysine side chains or the N-terminal amine.
  • Thiol-reactive PEGylation: PEG-maleimide reacts with cysteine thiols, allowing site-specific conjugation.
  • Click chemistry: Azide- or alkyne-functionalized PEG can be conjugated to peptides bearing complementary reactive groups, offering high selectivity.

Examples in Clinical Use

Several PEGylated peptides and proteins are FDA-approved:

  • PEG-interferon alpha (Pegasys, PegIntron) --- PEGylation extended interferon's half-life from 5 hours to 65-80 hours, transforming hepatitis C treatment from daily to weekly dosing.
  • Pegfilgrastim (Neulasta) --- PEGylated G-CSF for neutropenia, dosed once per chemotherapy cycle instead of daily.
  • Certolizumab pegol (Cimzia) --- PEGylated anti-TNF antibody fragment for rheumatoid arthritis and Crohn's disease.

Limitations

PEGylation is not without problems. PEG is non-biodegradable, and repeated dosing of PEGylated drugs can lead to vacuolar accumulation in tissues, particularly the kidney and liver. Anti-PEG antibodies have been detected in some patients, potentially accelerating clearance of PEGylated therapeutics on re-dosing. The large PEG chain can also reduce receptor binding affinity --- a trade-off between pharmacokinetics (longer half-life) and pharmacodynamics (weaker target engagement).

These limitations have driven interest in alternative approaches, particularly lipidation.

Lipidation: The Albumin Strategy

Lipidation is the attachment of fatty acid chains to a peptide. The fatty acid does not protect the peptide directly --- instead, it gives the peptide an affinity for serum albumin, the most abundant protein in blood plasma (~35-50 g/L, molecular weight 66.5 kDa).

How It Works

A fatty acid chain attached to the peptide binds reversibly and non-covalently to hydrophobic pockets on albumin. The peptide-albumin complex is too large for renal filtration (albumin alone is 66.5 kDa), and albumin has a plasma half-life of approximately 19 days thanks to FcRn-mediated recycling. By hitchhiking on albumin, the lipidated peptide inherits much of albumin's longevity.

The association is reversible: the lipidated peptide equilibrates between albumin-bound (long-lived, inactive) and free (short-lived, active) states. Only the free peptide can bind its receptor and produce a biological effect. This creates a built-in depot mechanism --- albumin slowly releases free peptide into the circulation, maintaining therapeutic levels over days.

The Chemistry of Acylation

Most lipidated peptide drugs use acylation: a fatty acid is covalently linked to a specific amino acid residue (typically a lysine side chain) through an amide bond. The fatty acid chain length, branching, and any spacer elements between the fatty acid and the peptide backbone all influence albumin binding affinity and, consequently, half-life.

A dramatic example of lipidation's pharmacokinetic impact: in comparative studies, a bivalirudin analog modified with a fatty acid showed a half-life of 212 minutes compared to 13.5 minutes for the unmodified peptide --- a roughly 15-fold increase from a single modification.

Semaglutide: A Case Study in Lipidation

Semaglutide is the definitive example of how lipidation transforms a peptide drug. Native GLP-1 has a half-life of about 2 minutes. Semaglutide lasts roughly 165 hours (about 7 days), enabling once-weekly dosing.

Novo Nordisk achieved this through three modifications:

  1. Amino acid substitution at position 8. Replacing alanine with alpha-aminoisobutyric acid (Aib) at position 2 of the GLP-1 sequence (position 8 of proglucagon numbering) renders the peptide resistant to DPP-4 cleavage --- the enzyme that destroys native GLP-1 within minutes.

  2. Amino acid substitution at position 34. Replacing lysine with arginine at position 34 prevents fatty acid attachment at the wrong site, ensuring the acylation occurs specifically at lysine 26.

  3. C18 fatty diacid acylation at lysine 26. A linker connects lysine 26 to a C18 (octadecandioic acid) fatty diacid through a mini-PEG spacer. This fatty diacid has higher albumin binding affinity than the C16 fatty acid used in the earlier drug liraglutide (which has a half-life of about 13 hours).

The progression from liraglutide (C16 fatty acid, 13-hour half-life, once-daily) to semaglutide (C18 fatty diacid, 165-hour half-life, once-weekly) demonstrates how optimizing the lipid moiety directly translates to clinical dosing convenience.

The Half-Life Ceiling

A 2024 study in PNAS investigated whether lipidation can be pushed further to achieve once-monthly dosing. The researchers concluded that lipidation alone has an inherent half-life ceiling of roughly one week for GLP-1-sized peptides. Neither longer fatty acid chains, PEGylation, polymer encapsulation, nor Fc fusion broke this barrier.

To achieve once-monthly semaglutide delivery, the team developed hydrogel microspheres with a cleavable linker designed for ~30-day release. In diet-induced obese mice, a single subcutaneous dose produced semaglutide release with an in vivo half-life of roughly 36 days and lean-sparing body weight loss of 20% over one month. This suggests that the next generation of long-acting peptides may need depot technologies rather than peptide modification alone.

Cyclization: Locking the Shape

Linear peptides are floppy. In solution, they adopt an ensemble of rapidly interconverting conformations, and only a fraction of these conformations match the shape needed to bind the target receptor. Cyclization constrains the peptide into a defined three-dimensional structure, with several benefits:

Increased binding affinity. A pre-organized peptide pays less entropic penalty upon binding its target, often resulting in stronger receptor interactions.

Protease resistance. Cyclic peptides lack free N- and C-termini --- the primary attack sites for exo-peptidases. The constrained backbone also limits access for endo-peptidases, which require the peptide to adopt extended conformations to fit into their active sites.

Improved membrane permeability. Some cyclic peptides can permeate cell membranes through conformational flexibility that allows intramolecular hydrogen bonds to shield backbone amide NH groups from water, enabling passive diffusion through lipid bilayers. Cyclosporine A, a cyclic peptide immunosuppressant, is the classic example.

Types of Cyclization

Head-to-tail (backbone) cyclization. The N-terminus is joined to the C-terminus through a peptide bond, forming a macrocyclic ring. This is the most common type, seen in natural products like cyclosporine A and daptomycin.

Side-chain-to-side-chain cyclization. Two amino acid side chains are connected by a chemical bridge --- typically a disulfide bond between two cysteines, a lactam bridge between lysine and glutamate/aspartate, or a thioether linkage. Many natural hormones use disulfide cyclization: oxytocin, vasopressin, and somatostatin all contain disulfide bridges that are required for biological activity.

Side-chain-to-backbone cyclization. One end of the bridge connects to a side chain and the other to the backbone nitrogen or C-terminal carboxyl.

Clinical Examples

Cyclic peptides span a wide range of therapeutic areas:

  • Octreotide (Sandostatin) --- a cyclic somatostatin analog with disulfide bridge, used for acromegaly and neuroendocrine tumors. The cyclization extends its half-life relative to native somatostatin (90 minutes vs. 3 minutes).
  • Daptomycin (Cubicin) --- a cyclic lipopeptide antibiotic approved for gram-positive bacterial infections.
  • Linaclotide (Linzess) --- a 14-amino-acid peptide with three disulfide bonds, approved for irritable bowel syndrome.
  • Ziconotide (Prialt) --- a synthetic version of omega-conotoxin MVIIA from cone snails, a 25-residue peptide with three disulfide bonds, approved for severe chronic pain.

Stapled Peptides: Reinforcing the Helix

Stapled peptides represent a specialized form of cyclization designed specifically to stabilize alpha-helical conformations. Many protein-protein interactions involve alpha-helical surfaces, but short peptides derived from these helices lose their structure in solution and cannot effectively mimic the interaction.

How Stapling Works

The hydrocarbon stapling technique, developed by Gregory Verdine's lab at Harvard in 2000, introduces two non-natural alpha,alpha-disubstituted amino acids bearing olefin (alkene) side chains at positions i and i+4 or i and i+7 along the peptide. A ruthenium-catalyzed ring-closing metathesis (RCM) reaction then joins the two olefin chains, forming an all-hydrocarbon cross-link that locks the peptide into a helical conformation.

The resulting stapled peptide has several desirable properties:

  • Increased helicity. The hydrocarbon bridge forces the backbone into an alpha-helical twist, often increasing helical content from 20-30% to 80-90%.
  • Protease resistance. The constrained backbone and non-natural amino acids resist enzymatic cleavage.
  • Cell penetration. The hydrocarbon staple increases lipophilicity, enabling active transport into cells --- a property that most peptides lack.
  • Enhanced target binding. The pre-formed helix presents the binding interface in the correct geometry, reducing the entropic cost of binding.

Key Clinical Example: Sulanemadlin (ALRN-6924)

Sulanemadlin (ALRN-6924), developed by Aileron Therapeutics, is the first stapled peptide to enter clinical trials for cancer therapy. It mimics a helical segment of the p53 tumor suppressor protein and binds to both MDM2 and MDMX --- two proteins that normally inhibit p53 function.

At high doses, ALRN-6924 reactivates p53-dependent anti-cancer signaling in tumors with wild-type p53. At lower doses, it transiently arrests the cell cycle in healthy tissues, protecting them from chemotherapy-induced damage without protecting p53-mutant cancer cells. Phase 1 results showed dose-dependent pharmacokinetics, p53 pathway activation (measured by serum MIC-1 levels), and manageable side effects (GI symptoms, fatigue, anemia).

Expanding the Toolkit

A 2025 review in ChemBioChem described advances beyond simple mono-stapling:

  • Stitched peptides use two sequential RCM reactions connected by a central spiro junction, creating a double constraint across multiple helical turns. This further increases helicity, protease resistance, and cell penetration.
  • Aza-stapled peptides replace one or both olefin-bearing residues with aza-amino acids, providing alternative stereochemistry and backbone flexibility.
  • Carbocyclic anchoring residues (cyclobutane-derived alpha,alpha-disubstituted amino acids) provide rigidified starting points for the staple, reducing conformational heterogeneity.

Stapled peptides are now being explored for targets beyond oncology, including antimicrobial applications (stapled cecropin A analogs showed enhanced antibacterial potency and reduced inflammation in mouse peritonitis models) and immune modulation (stapled FOXP3 peptides that disrupt regulatory T cell function).

Other Modification Strategies

D-Amino Acid Substitution

Replacing L-amino acids with their D-enantiomers renders the peptide bond invisible to most natural proteases, which are stereospecific for L-amino acids. D-amino acid substitution at key cleavage sites can dramatically increase plasma stability. The trade-off is that D-substitutions can alter receptor binding if placed within the pharmacophore.

N-Methylation

Adding a methyl group to the backbone nitrogen of specific residues blocks hydrogen bond donation and sterically hinders protease access. Cyclosporine A uses extensive N-methylation as part of its stability and membrane permeability strategy. N-methylation can also improve oral bioavailability by increasing lipophilicity.

Glycosylation

Attaching sugar moieties (glycans) to peptides increases solubility, reduces aggregation, and can extend half-life through increased hydrodynamic radius and reduced renal clearance. Glycosylation also modulates immune recognition. Erythropoietin (EPO) relies heavily on glycosylation for its long plasma half-life --- the hyperglycosylated version (darbepoetin alfa) has three times the half-life of native EPO.

XTEN and PASylation

These strategies fuse biodegradable polypeptide extensions to the therapeutic peptide. XTEN uses unstructured sequences of six amino acids (A, E, G, P, S, T) that increase hydrodynamic radius without adding structure. PASylation uses Pro-Ala-Ser repeats. Both approaches mimic the size-increasing effect of PEGylation but are fully biodegradable, avoiding the tissue accumulation concerns associated with PEG.

Comparing the Approaches

ModificationMechanism of Half-Life ExtensionTypical Half-Life GainKey AdvantageKey Limitation
PEGylationIncreased hydrodynamic size; steric shieldingHours to daysWell-established; broad applicabilityNon-biodegradable; anti-PEG antibodies; reduced receptor affinity
LipidationAlbumin binding; reduced renal clearanceHours to ~1 weekBiodegradable; maintains receptor access (free fraction)~1-week ceiling for lipidation alone; requires albumin binding optimization
CyclizationProtease resistance; conformational stability3-30x over linear parentNo molecular weight increase; can improve oral bioavailabilityNot applicable to all sequences; may alter pharmacology
StaplingHelical stabilization; protease resistance; cell penetrationVariable (structure-dependent)Enables intracellular targets; maintains helical binding interfaceLimited to helical peptides; hemolysis risk; complex synthesis
D-amino acidsProtease resistance5-50x over L-parentSimple modification; fully biodegradableCan disrupt receptor binding; alters backbone geometry
XTEN/PASylationIncreased hydrodynamic sizeHours to daysBiodegradable; no immune concernsIncreases molecular weight; production complexity

FAQ

What is the most common peptide modification in FDA-approved drugs?

Disulfide cyclization and amino acid substitution (including D-amino acids) are the most common modifications in approved peptide drugs. PEGylation is the most common polymer modification. Lipidation (acylation) has gained ground rapidly with the success of liraglutide, semaglutide, and tirzepatide.

Why does semaglutide last a week while native GLP-1 lasts 2 minutes?

Three modifications account for the difference. An Aib substitution at position 8 blocks DPP-4 cleavage. A C18 fatty diacid attached at lysine 26 via a mini-PEG spacer enables tight albumin binding, which prevents renal filtration and creates a slow-release reservoir in the blood. An arginine substitution at position 34 ensures the fatty acid attaches at the correct site. Together, these changes extend the half-life from ~2 minutes to ~165 hours.

Can peptide modifications enable oral delivery?

Yes, though with significant challenges. Cyclization and N-methylation can improve oral bioavailability by increasing membrane permeability and protease resistance. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to facilitate gastric absorption, achieving about 1% oral bioavailability --- low, but sufficient at higher doses. For more on delivery routes, see routes of peptide administration.

What is the difference between PEGylation and lipidation?

PEGylation attaches a large synthetic polymer (PEG) directly to the peptide, physically shielding it from proteases and preventing renal filtration through size increase. Lipidation attaches a fatty acid chain that causes the peptide to bind reversibly to serum albumin, borrowing albumin's long half-life. PEGylation produces a permanent size increase; lipidation creates a dynamic equilibrium between albumin-bound and free forms. Lipidation is biodegradable; PEG is not.

Are stapled peptides approved as drugs?

No stapled peptide has received FDA approval as of early 2026. Sulanemadlin (ALRN-6924) advanced furthest in clinical development, reaching Phase 2 trials for cancer and chemoprotection. ALRN-5281, a stapled GHRH agonist, completed Phase 1. The technology is still maturing, with ongoing work to optimize toxicity profiles and develop design rules for cellular permeability.

What modifications does tirzepatide use?

Tirzepatide uses a C20 fatty diacid (eicosanedioic acid) attached to lysine 20 via a linker containing a gamma-glutamic acid spacer. Like semaglutide, this enables albumin binding and weekly dosing. Tirzepatide also incorporates Aib at position 2 for DPP-4 resistance and several non-native amino acid substitutions that modulate its dual GLP-1R/GIPR agonist activity.

The Bottom Line

Peptide modification is the engineering discipline that transforms biologically active but pharmacokinetically impractical molecules into viable drugs. PEGylation solves the size problem. Lipidation solves the size problem while remaining biodegradable. Cyclization solves the shape and stability problem. Stapling solves the intracellular access problem.

The most successful modern peptide drugs combine multiple modifications. Semaglutide uses amino acid substitution plus lipidation. Tirzepatide uses amino acid substitution plus lipidation with a different fatty acid architecture. Future peptide drugs will likely layer modifications even further --- potentially combining cyclization with lipidation, or stapling with PEGylation --- to access targets and dosing regimens that no single modification can achieve alone.

For a deeper look at the biochemical foundations behind these modifications, see our guides on what peptides are and how peptides work at the molecular level.

References

  1. Veronese, F.M. & Mero, A. (2008). The impact of PEGylation on biological therapies. BioDrugs, 22(5), 315-329.

  2. Zhang, C., et al. (2024). Research progress on the PEGylation of therapeutic proteins and peptides. PMC. PMC10960368

  3. Knudsen, L.B., et al. (2000). Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry, 43(9), 1664-1669.

  4. Lau, J., et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370-7380.

  5. Marre, M., et al. (2024). The limitation of lipidation: Conversion of semaglutide from once-weekly to once-monthly dosing. PNAS, 121(48), e2415815121. doi:10.1073/pnas.2415815121

  6. Blaskovich, M.A.T. (2025). Overcoming Challenges in the Metabolism of Peptide Therapeutics. Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.5c02276

  7. Guerlavais, V. & Sawyer, T.K. (2023). Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized alpha-Helical Peptide in Clinical Development. Journal of Medicinal Chemistry, 66(14), 9401-9417. doi:10.1021/acs.jmedchem.3c00623

  8. Li, X., et al. (2025). Advances in Hydrocarbon Stapled Peptides via Ring-Closing Metathesis. ChemBioChem. doi:10.1002/cbic.202500527

  9. Liu, X., et al. (2025). Systematic All-Hydrocarbon Stapling Analysis for Cecropin A. Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.4c02852

  10. Yang, Z., et al. (2025). Therapeutic stapled peptides: Efficacy and molecular targets. Pharmacological Research, 201, 107083. doi:10.1016/j.phrs.2024.107083

  11. Li, C., et al. (2025). Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy. PMC. PMC12062087

  12. Chen, Y., et al. (2025). Advances in Peptidomimetics for Next-Generation Therapeutics. Chemical Reviews. doi:10.1021/acs.chemrev.4c00989

  13. Verdine, G.L. & Hilinski, G.J. (2012). Stapled peptides for intracellular drug targets. Methods in Enzymology, 503, 3-33.

  14. Walensky, L.D., et al. (2004). Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 305(5689), 1466-1470.

  15. Bachem. Bioavailability of Peptides. bachem.com